Previous Close | 0.335 |
1-Year Change | -33% |
6-Months Change | -72.08% |
3-Months Change | -11.38% |
Moving Avg (50d) | 0.3644 |
Moving Avg (200d) | 1.0524 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 32.9M |
Beta (3-Years) | 1.43 |
Revenue Growth (ttm) | 26.09% |
Net Profit Margin (ttm) | -189.81% |
Return On Assets (ttm) | -63.89% |
EPS (ttm) | -3.07 |
PE Ratio (ttm) | -0.11 |
Dividend Yield | % |
Asset Description: | FibroGen, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.343 | 0.332 | 0.325 | 0.315 | 0.297 | 0.28 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |